|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||28.26 - 29.01|
|52 Week Range||15.15 - 29.01|
|PE Ratio (TTM)||61.54|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||21.70|
Deutsche Bank upgraded Myriad Genetics, Inc. (NASDAQ: MYGN ), as it believes the risk/reward is now balanced following the company below-consensus sales and earnings per share guidance for 2018. The firm ...
Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.
The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.